ストックスクリーナーアプリを入手
26.36
2.29%
0.59
アフターアワーズ：
26.36
前日終値:
$25.77
開ける：
$25.7
24時間の取引高:
83.03M
Relative Volume:
2.11
時価総額：
$149.38B
収益：
$59.37B
当期純損益:
$4.25B
株価収益率:
14.40
EPS:
1.83
ネットキャッシュフロー:
$8.23B
1週間 パフォーマンス:
+3.05%
1か月 パフォーマンス:
+5.69%
6か月 パフォーマンス:
-4.97%
1年 パフォーマンス:
-4.60%
1日の値動き範囲:
$25.70
$26.49
1週間の範囲:
$25.22
$26.52
52週間の値動き範囲:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.36 | 149.38B | 59.37B | 4.25B | 8.23B | 0.74 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Pfizer Inc. (PFE) Is Among the Best Dividend Leaders to Buy According to Wall Street Analysts - Yahoo Finance
Market Today: Qualcomm's Legal Victory and Pfizer's FDA Approval Highlight Key Developments - GuruFocus.com
Investors Purchase High Volume of Call Options on Pfizer (NYSE:PFE) - MarketBeat
Pfizer cost cutting leads to Tampa layoffs - The Business Journals
Pfizer gets FDA accelerated approval for Braftovi (PFE:NYSE) - Seeking Alpha
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment - Marketscreener.com
Pfizer to lay off 62 in Tampa - Business Observer
Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer - Business Wire
Pfizer (NYSE:PFE) Trading Up 1.6%What's Next? - MarketBeat
Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now? - Insider Monkey
Phenobarbital Market CAGR of 5% Trends and Growth Analysis By 2024 to 2031 | Sanofi, Pfizer Inc., Novartis AG, - EIN News
Principal Financial Group Inc. Sells 1,349,308 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts - BioSpace
Judge Wrongly Axed $107M IP Verdict, Pfizer Tells Fed. Circ. - Law360
Why Pfizer (PFE) Dipped More Than Broader Market Today - Yahoo Finance
Pfizer Colleagues Celebrate Native American Heritage - Pfizer
Pfizer (NYSE:PFE) Trading 0.4% HigherTime to Buy? - MarketBeat
Liposomal Doxorubicin Market to Witness Massive Growth | Major Giants Pfizer, Ipsen, Johnson & Johnson - openPR
Is Pfizer Stock A Buy After Rallying On Its 2025 Guidance? - Investor's Business Daily
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26? - Yahoo Finance
PFIZER INC : Gets a Neutral rating from UBS - Marketscreener.com
Stomach Cancer Drugs Market Future Business Opportunities - openPR
Pfizer's SWOT analysis: stock outlook amid pipeline progress and cost cuts - Investing.com
Pfizer Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Jim Cramer’s Take on Pfizer (PFE): Can CEO Dr. Bourla’s Bold Strategy Overcome Debt and Turn the Stock Around? - Yahoo Finance
Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis) (NYSE:PFE) - Seeking Alpha
Satellite Images Reveal Russian Military Movements in Syria - Yahoo Finance
Pfizer (NYSE:PFE) Shares Down 0.4% Following Analyst Downgrade - MarketBeat
Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call (PFE) - Seeking Alpha
Pfizer eyes 2025 revenue growth despite post-COVID challenges, activist pressure - MM+M Online
Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations - Yahoo Finance
Pfizer reiterated at Market Perform by analyst following FY25 guidance - Investing.com Canada
Truist cuts Pfizer shares target, retains buy rating on growth projections - Investing.com
Pfizer: Jefferies confirms its analysis on the stock - Marketscreener.com
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy - Yahoo! Voices
Trending tickers: The latest investor updates on Pfizer, Micron, Nissan, Teva and National Grid - Yahoo Finance UK
Pfizer provides full-year 2025 guidance - The Pharma Letter
Pfizer aims to quell concern about its vaccine business under Trump - Crain's New York Business
Pfizer Sets 2025 Outlook, Confirms 2024 Guidance - Mirage News
Oncology Drugs Market Huge Growth in Future Scope 2024-2031 | - openPR
Epilepsy Drugs Market Detailed In New Research Report 2024 | - openPR
Pfizer Stock Jumps After Reassuring 2025 Guidance - The Wall Street Journal
Medicare Part D Redesign: Pfizer’s Catastrophic Phase Discounts Will Total $1.5bn In 2025 - Citeline News & Insights
Pfizer Confident On Policy Outlook Heading Into Trump Administration - Citeline News & Insights
Pfizer Stock Surges 4% on Reaffirmed Earnings Guidance, Don't Buy Shares Yet - Money Morning
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Trump: Will 'Knock Out' Pharma Middlemen - Marketscreener.com
Pfizer (NYSE:PFE) Trading Up 4%Still a Buy? - MarketBeat
Pfizer (NYSE:PFE) Shares Gap UpStill a Buy? - MarketBeat
Trump ‘Middleman’ Remark Sinks CVS, UnitedHealth, Cigna Shares - MSN
Health Insurers Fall as Pfizer CEO Says Trump Wants PBM Reform - Yahoo Finance
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
1.48%
大文字化:
|
ボリューム (24 時間):